US2009081256A1PendingUtilityA1

Transgenic plant-based vaccines

67
Assignee: UNIV LOMA LINDAPriority: Oct 7, 1997Filed: Aug 12, 2008Published: Mar 26, 2009
Est. expiryOct 7, 2017(expired)· nominal 20-yr term from priority
A61K 2039/6037C07K 14/62C12N 15/8258A61K 48/00C07K 2319/55C07K 14/28C12N 9/88A61K 39/12C07K 2319/00C12N 15/8216A61P 29/00C12N 2720/12334A61K 39/00
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of inducing partial or complete immunity to an infectious disease in a mammal comprising providing to the mammal for oral consumption an effective amount of a protein complex comprising five monomeric fusion proteins.

Claims

exact text as granted — not AI-modified
1 . A method of producing an immunogen in a plant comprising cultivating a transgenic plant transformed with a DNA construct that encodes, upon expression in a plant cell, a protein complex comprising a multimeric cholera toxin B subunit and a an immunogenic antigen from a causal factor of a first mammalian disease under conditions effective to express the protein complex. 
     
     
         2 . A method of producing an immunogen in a plant comprising cultivating a transgenic plant transformed with a DNA construct that encodes, upon expression in a plant cell, a protein complex comprising a cholera toxin A2 subunit, a multimeric cholera toxin B subunit, a first immunogenic antigen from a causal factor of a first mammalian disease, and a second immunogenic antigen from a causal factor of a second mammalian disease under conditions effective to express the protein complex. 
     
     
         3 . The method of  claim 1 , where the multimeric cholera toxin B subunit comprises five monomeric fusion proteins. 
     
     
         4 . The method of  claim 3 , where the immunogenic antigen is NSP4 antigen from rotavirus, and where each fusion protein further comprises a cholera toxin B subunit linked to an NSP4 antigen from rotavirus. 
     
     
         5 . The method of  claim 3 , where the protein complex further comprises ETEC fimbrial antigen CFA/1 from enterotoxigenic  E. coli.    
     
     
         6 . The method of  claim 1 , where the DNA construct comprises a bidirectional promoter controlling transcription of the DNA construct. 
     
     
         7 . A plant produced according to the method of  claim 1 . 
     
     
         8 . A plant produced according to the method of  claim 3 . 
     
     
         9 . A plant produced according to the method of  claim 4 . 
     
     
         10 . A plant produced according to the method of  claim 5 . 
     
     
         11 . A plant produced according to the method of  claim 6 . 
     
     
         12 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 7 . 
     
     
         13 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 8 . 
     
     
         14 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 9 . 
     
     
         15 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 10 . 
     
     
         16 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 11 . 
     
     
         17 . The method of  claim 2 , where the multimeric cholera toxin B subunit comprises five monomeric fusion proteins. 
     
     
         18 . The method of  claim 17 , where the first immunogenic antigen is NSP4 antigen from rotavirus, and where each fusion protein further comprises a cholera toxin B subunit linked to an NSP4 antigen from rotavirus. 
     
     
         19 . The method of  claim 17 , where the second immuogenic antigen is ETEC fimbrial antigen CFA/1 from enterotoxigenic  E. coli.    
     
     
         20 . The method of  claim 2 , where the DNA construct comprises a bidirectional promoter controlling transcription of the DNA construct. 
     
     
         21 . A plant produced according to the method of  claim 2 . 
     
     
         22 . A plant produced according to the method of  claim 17 . 
     
     
         23 . A plant produced according to the method of  claim 18 . 
     
     
         24 . A plant produced according to the method of  claim 19 . 
     
     
         25 . A plant produced according to the method of  claim 20 . 
     
     
         26 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 21 . 
     
     
         27 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 22 . 
     
     
         28 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 23 . 
     
     
         29 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 24 . 
     
     
         30 . A method for the prevention of multiple types of acute gastroenteritis simultaneously in a mammal comprising providing to the mammal for oral consumption an effective amount of the plant of  claim 25 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.